IDXXIDEXX Laboratories, Inc.

$48B

Q1 2022 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$837M+7.6% YoY

Gross Profit

$499M59.6% margin

Operating Income

$248M29.7% margin

Net Income

$194M23.2% margin

EPS (Diluted)

$2.27

QoQ Revenue Growth

+4.4%

Cash Flow

Operating Cash Flow

$115M

Free Cash Flow

$73M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$2.6B

Total Liabilities

$2.0B

Stockholders' Equity

$640M

Cash & Equivalents

$205M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$837M	$778M	+7.6%
Gross Profit	$499M	$471M	+5.9%
Operating Income	$248M	$248M	+0.3%
Net Income	$194M	$204M	-5.0%

Revenue Segments

Up Front Customer Loyalty Programs And Volume Commitment Programs

$3.0B98%

Reagent Rental Programs

$37M1%

Extended Warranties And Post Contract Support

$15M0%

Instrument Rebate Programs

$3M0%

Geographic Segments

UNITED STATES

$526M63%

EMEA

$174M21%

Asia Pacific

$84M10%

CANADA

$35M4%

Latin America

$18M2%

IDXX Q1 2022 Earnings — IDEXX Laboratories, Inc. Revenue & Financial Results | Market Cap Arena